S
17.39
-0.52 (-2.90%)
| Previous Close | 17.91 |
| Open | 17.98 |
| Volume | 3,473,548 |
| Avg. Volume (3M) | 13,113,708 |
| Market Cap | 1,820,246,016 |
| Price / Earnings (Forward) | 6.68 |
| Price / Sales | 0.760 |
| Price / Book | 1.33 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Sarepta Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.5
| Analyst Consensus | -0.5 |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 96.33% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Wells Fargo, 187.52%) | Buy |
| 50.00 (Needham, 187.52%) | Hold | |
| 50.00 (BMO Capital, 187.52%) | Hold | |
| Median | 19.50 (12.13%) | |
| Low | 5.00 (HC Wainwright & Co., -71.25%) | Sell |
| Average | 23.00 (32.26%) | |
| Total | 5 Buy, 13 Hold, 4 Sell | |
| Avg. Price @ Call | 16.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 15 Sep 2025 | 22.00 (26.51%) | Buy | 17.39 |
| Leerink Partners | 09 Sep 2025 | 15.00 (-13.74%) | Hold | 17.64 |
| HC Wainwright & Co. | 25 Aug 2025 | 5.00 (-71.25%) | Sell | 18.06 |
| 25 Jun 2025 | 10.00 (-42.50%) | Sell | 17.46 | |
| B of A Securities | 21 Aug 2025 | 16.00 (-7.99%) | Sell | 20.06 |
| 20 Aug 2025 | 17.00 (-2.24%) | Sell | 20.58 | |
| Deutsche Bank | 15 Aug 2025 | 12.00 (-30.99%) | Sell | 21.81 |
| 17 Jun 2025 | 25.00 (43.76%) | Hold | 21.56 | |
| Goldman Sachs | 07 Aug 2025 | 19.00 (9.26%) | Hold | 17.96 |
| 17 Jun 2025 | 29.00 (66.76%) | Hold | 21.56 | |
| Wells Fargo | 07 Aug 2025 | 50.00 (187.52%) | Buy | 17.96 |
| 24 Jul 2025 | 48.00 (176.02%) | Buy | 12.88 | |
| Barclays | 30 Jul 2025 | 22.00 (26.51%) | Hold | 16.75 |
| 29 Jul 2025 | 22.00 (26.51%) | Hold | 15.83 | |
| BMO Capital | 29 Jul 2025 | 50.00 (187.52%) | Hold | 15.83 |
| 22 Jul 2025 | 25.00 (43.76%) | Hold | 13.62 | |
| Bernstein | 29 Jul 2025 | 13.00 (-25.24%) | Hold | 15.83 |
| JP Morgan | 29 Jul 2025 | 24.00 (38.01%) | Hold | 15.83 |
| 21 Jul 2025 | 20.00 (15.01%) | Buy | 13.32 | |
| Morgan Stanley | 29 Jul 2025 | 20.00 (15.01%) | Hold | 15.83 |
| 17 Jun 2025 | 40.00 (130.02%) | Hold | 21.56 | |
| Oppenheimer | 29 Jul 2025 | 37.00 (112.77%) | Buy | 15.83 |
| 18 Jul 2025 | 41.00 (135.77%) | Buy | 14.08 | |
| Piper Sandler | 29 Jul 2025 | 15.00 (-13.74%) | Hold | 15.83 |
| 22 Jul 2025 | 11.00 (-36.75%) | Hold | 13.62 | |
| Citigroup | 24 Jul 2025 | 7.00 (-59.75%) | Sell | 12.88 |
| Jefferies | 24 Jul 2025 | 35.00 (101.27%) | Buy | 12.88 |
| Leerink Swann | 21 Jul 2025 | 10.00 (-42.50%) | Hold | 13.32 |
| Mizuho | 21 Jul 2025 | 14.00 (-19.49%) | Hold | 13.32 |
| 18 Jun 2025 | 40.00 (130.02%) | Buy | 20.77 | |
| UBS | 21 Jul 2025 | 12.00 (-30.99%) | Hold | 13.32 |
| Needham | 18 Jul 2025 | 50.00 (187.52%) | Hold | 14.08 |
| 17 Jul 2025 | 50.00 (187.52%) | Buy | 21.97 | |
| Baird | 17 Jul 2025 | 35.00 (101.27%) | Buy | 21.97 |
| 17 Jun 2025 | 30.00 (72.51%) | Buy | 21.56 | |
| RBC Capital | 17 Jul 2025 | 23.00 (32.26%) | Hold | 21.97 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ESTEPAN IAN MICHAEL | 18.95 | - | 143,875 | 2,726,431 |
| RODINO-KLAPAC LOUISE | 18.95 | - | 143,875 | 2,726,431 |
| ROTHFUSS CRISTIN | 18.95 | - | 118,875 | 2,252,681 |
| WONG RYAN HO-YAN | 18.95 | - | 118,875 | 2,252,681 |
| Aggregate Net Quantity | 525,500 | |||
| Aggregate Net Value ($) | 9,958,225 | |||
| Aggregate Avg. Buy ($) | 18.95 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROTHFUSS CRISTIN | Officer | 03 Sep 2025 | Acquired (+) | 118,875 | 18.95 | 2,252,681 |
| ESTEPAN IAN MICHAEL | Officer | 03 Sep 2025 | Acquired (+) | 143,875 | 18.95 | 2,726,431 |
| WONG RYAN HO-YAN | Officer | 03 Sep 2025 | Acquired (+) | 118,875 | 18.95 | 2,252,681 |
| RODINO-KLAPAC LOUISE | Officer | 03 Sep 2025 | Acquired (+) | 143,875 | 18.95 | 2,726,431 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |